BERNHARDT GEORGE ZEIHER;ASTELLAS PHARMA EUROPE LTD;ANDREAS JOHANNIS KARAS;CHRISTOPHER MARK LONGSHAW;LETICIA DELGADO-HERRERA
发明人:
ANDREAS JOHANNIS KARAS,CHRISTOPHER MARK LONGSHAW,LETICIA DELGADO-HERRERA,BERNHARDT GEORGE ZEIHER
申请号：
IL25657617
公开号：
IL256576D0
申请日:
2017.12.25
申请国别(地区):
IL
年份:
2018
代理人:
摘要：
The present inventors provides one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile-associated disease (CDAD) in a patient according to a dosage regimen comprising: (1) administering to the patient in an initial course of treatment 200 mg of the tiacumicin compound twice a day； (2) monitoring the efficacy of the initial course of treatment in the patient by means of monitoring changes of one or more indicators of CDI or CDAD； (3) assessing whether there is a positive change of the one or the more of the indicators； and (4) switching to an intermittent course of treatment by administering to the patient 200 mg of the tiacumicin compound every other day if the one or the more of the indicators of CDI or CDAD are positively changed. Further the invention provides the use of the tiacumicin compound to reduce recurrence in a patient suffering from CDI or CDAD.
